3776.ppt
-
Upload
brucelee55 -
Category
Health & Medicine
-
view
219 -
download
0
Transcript of 3776.ppt
![Page 1: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/1.jpg)
![Page 2: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/2.jpg)
Sigrid Stroobantsdept of Nuclear Medicine
Leuven, Belgium
PET and PET/CT in lung cancer
![Page 3: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/3.jpg)
PET and PET/CT in Lung Ca
• Characterization of a solitaire pulmonary nodule
• Mediastinal staging
• Distant staging
• (Radiotherapy planning)
• (Treatment response assessment)
![Page 4: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/4.jpg)
Solitary Pulmonary Nodules
• FDG-PET useful to distinguish between benign vs malignant nodules– many well documented prospective series– meta-analysis Gould et al; JAMA, 2001
• sensitivity 96% - specificity 78% - accuracy 91%
• Limits– sensitivity: subcentimetric nodules - carcinoids - BAC (GGO)– specificity: inflammatory/granulomatous lesions
• Use of threshold values (e.g. SUV >2.5) not superior
• Clinical use– close FU in PET negative nodules > 1 - 1.5 cm without GGO
![Page 5: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/5.jpg)
Mediastinal staging
• FDG-PET more accurate than CT in mediastinal LN staging– many well documented prospective series– several meta-analyses
Gould et al; Ann Intern Med 2003• Sensitivity 89% (vs. 65%) - Specificity 92% (vs. 80%)
• Limits– spatial resolution (N1 vs N2/N2; adjacent LN in central T)– sensitivity: LNs with minimal tumour load– specificity: inflammatory nodes– accuracy dependent on LN size?
![Page 6: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/6.jpg)
Mediastinal staging
Langen et al, Eur J Cardio Thor Surgery 2006
![Page 7: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/7.jpg)
• Clinical use– high NPV of PET in LN staging omit invasive tests
• BUT “side conditions”– adequate FDG-uptake of primary tumour– caution with central tumours and hilar N1 disease– ? Large nodes on CT
• Always confirm PET+ nodes
Mediastinal staging
![Page 8: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/8.jpg)
• PET improves conventional staging (CS)– detection of lesions missed on CS (5 - 20%)– differentiation of lesions equivocal on CS (7 – 19%)
• caution if lesion < 1 cm !• low sensitivity for brain mets
– change in overall stage in 27 - 62% (up > down)– never alter treatment based on PET+ only
• PET impacts on choice of treatment in 25-41%
Distant Staging
![Page 9: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/9.jpg)
Question?Do you have access to PET or PET/CT1. No
2. Yes, in own hospital
3. Yes, in other hospital
![Page 10: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/10.jpg)
QuestionDo you discuss PET images in a multi discipl. round
1. Yes and radiologist / Nuc Med is present
2. Yes, but no radiologist / Nuc Med is present
3. No, I only rely on the report
![Page 11: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/11.jpg)
Case 1
![Page 12: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/12.jpg)
Case 1
• Male, 55 y, smoker (30 pack y)• Incidental finding of a 1 cm node in LLL• No previous imaging data, normal
bronchoscopy
![Page 13: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/13.jpg)
QuestionWhat would be your next step?
1. Repeat CT scan after 3 months
2. PET
3. Trans thoracic biopsy
4. Surgery (VATS, thoracotomy)
Case 1
![Page 14: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/14.jpg)
Mediastinoscopy + 4LSquamous ca T1N2
Case 1
![Page 15: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/15.jpg)
Case 2
![Page 16: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/16.jpg)
Case 2
• Male, 64 y, painter, smoker (35 pack y, stopped 2y ago)• Persistent cough, dyspnoe, malaise• Chest XR and CT
• Bronchoscopy with aspiration negative• EBUS guided biopsy LLL: squamous cell carcinoma• Brain and abdominal CT negative for M+, normal CEA
![Page 17: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/17.jpg)
Case 2
![Page 18: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/18.jpg)
1. Chemotherapy (stage IV – contralateral lung)
2. Chemoradiation (stage III B – N3)
3. EBUS + FNA
4. Mediastinoscopy
QuestionWhat would be your next step?
Case 2
![Page 19: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/19.jpg)
Case 2
Mediastinoscopy: negative Lobectomy + lymphadenectomie (silicosis)sT2N0
![Page 20: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/20.jpg)
Case 3
![Page 21: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/21.jpg)
Case 3• Male, 61 y, non-smoker• 1991 Cardiac transplant for sarcoidosis R/ Imuran• Co-morbidity Left Hemiparesis 1990 (CVA)
Chronic renal impairmentLung emboli (1994) R/ Marcoumar
• Incidental finding of SPN in RUL during routine annual visit
• Bronchoscopy normal
![Page 22: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/22.jpg)
Case 3
![Page 23: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/23.jpg)
1. Surgery of both lesions in same anesthesia
2. Surgery of limb lesion
3. Surgery of lung lesion
4. Close follow up
QuestionWhat would be your next step?
Case 3
![Page 24: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/24.jpg)
• Surgery of the limb
Pathology = Ancient Schwannoma
• Repeat Chest CT (2 months later)
Case 3
![Page 25: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/25.jpg)
Case 4
![Page 26: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/26.jpg)
Case 4• Female, 69 y, housewife, smoker (45 pack y)• 1990 Larynx ca R/ surgery + radiotherapy• Referred for second opinion
– Chest CT 2 lesions in LUL + mediastinal LN (levels 4R-4L-7)
– Bronchoscopy + aspiration cytology normal– Mediastinoscopy : no tumor– Screening M+ (CT abdomen – CT brain) negative
![Page 27: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/27.jpg)
QuestionWhat would be your next step?
1. PET
2. Trans thoracic biopsy
3. EBUS guided biopsy of lung lesion
4. Surgical exploration and if malignant resection (T4 N0-1M0)
Case 4
![Page 28: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/28.jpg)
• EBUS guided biopsy
Pathology atypical hyperplasia
• PET
Case 4
![Page 29: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/29.jpg)
Case 4
![Page 30: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/30.jpg)
QuestionHow would you interpret this PET scan?
1. All inflammatory disease, no tumor present
2. Malignant lesions in LUL with N3 LN, no metastasis
3. Malignant lesions in LUL with N3 LN and bone M+
Case 4
![Page 31: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/31.jpg)
Case 4
![Page 32: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/32.jpg)
Case 4
• Thoracoscopy for pathology
• T4 Nx M1 • Palliative chemotherapy (Cisplatin-Gemcitabine)• Zometa
undifferentiated large cell ca
![Page 33: 3776.ppt](https://reader036.fdocuments.us/reader036/viewer/2022070317/556550e7d8b42a77078b4971/html5/thumbnails/33.jpg)
Thank You !